ইঙ্গিত ও ব্যবহার
Bevixa 400 এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Dosage: Patients should continue treatment until the disease progresses or the side effects become unacceptable. Metastatic Colorectal Cancer (mCRC): The recommended doses are 5 mg/kg or 10 mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy. Give 5 mg/kg when used in combination with bolus-IFL. Give 10 mg/kg when used in combination with FOLFOX4. Give 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients whose disease has progressed on a first-line Bevacizumab-containing regimen. Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC): The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel. Glioblastoma: The recommended dose is 10 mg/kg every 2 weeks. Metastatic Renal Cell Carcinoma (mRCC): The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa. Cervical Cancer: The recommended dose of Bevacizumab is 15 mg/kg every 3 weeks, given as an intravenous infusion in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan. Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The recommended dose is 10 mg/kg every 2 weeks in combination with one of the following intravenous chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg every 3 weeks in combination with topotecan (every 3 weeks). Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: The recommended dose is 15 mg/kg every 3 weeks when given in combination with carboplatin and paclitaxel for 6 cycles and up to 8 cycles, followed by continued use of Bevacizumab 15 mg/kg every 3 weeks as a single agent until the disease progresses. Alternatively, 15 mg/kg every 3 weeks when given in combination with carboplatin and gemcitabine for 6 cycles and up to 10 cycles, followed by continued use of Bevacizumab 15 mg/kg every 3 weeks as a single agent until the disease progresses.
পার্শ্বপ্রতিক্রিয়া
The most common side effects of Bevacizumab (those occurring in more than 10% of patients and at least twice as often as in the control group) are nosebleeds, headache, high blood pressure, runny or inflamed nose, protein in the urine, changes in taste, dry skin, rectal bleeding, tear-production problems, back pain and severe peeling or flaking of the skin.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Perforation or fistula: Discontinue Bevixa if perforation or fistula occurs. Arterial thromboembolic events (ATE), such as myocardial infarction or cerebral infarction: Discontinue Bevixa for severe ATE. Venous thromboembolic events (VTE): Discontinue Bevixa for life-threatening VTE. Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend Bevixa if blood pressure is not medically controlled. Discontinue Bevixa for hypertensive crisis or hypertensive encephalopathy. Posterior reversible encephalopathy syndrome (PRES): Discontinue Bevixa. Proteinuria: Monitor urine protein. Discontinue Bevixa for nephrotic syndrome. Temporarily suspend Bevixa for moderate proteinuria. Infusion reactions: Stop Bevixa for severe infusion reactions. Embryo-fetal toxicity: Advise females of the potential risk to a fetus and the need to use effective contraception. Ovarian failure: Advise females of the potential risk.
নিষেধাজ্ঞা
The manufacturer’s labeling does not list any contraindications for this medicine.